CLASS ACTION UPDATE for GS, XRAY and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
The Goldman Sachs Group, Inc. (NYSE: GS) Class Period: February 28, 2014 - December 17, 2018 Lead Plaintiff Deadline: February 19, 2019 Join the action: https://www.zlk.com/pslra-1/the-goldman-sachs-group-inc-loss-form?wire=3
The lawsuit alleges: The Goldman Sachs Group, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Goldman Sachs participated in a fraud and money-laundering scheme in collusion with 1Malaysia Development Bhd., a Malaysian state-owned investment fund; (2) the foregoing conduct, when revealed, would foreseeably subject Goldman Sachs to heightened regulatory investigations and enforcement; and (3) as a result, Goldman Sachs’s public statements were materially false and misleading at all relevant times.
To learn more about the The Goldman Sachs Group, Inc. class action contact email@example.com.
Dentsply Sirona, Inc. (NASDAQ: XRAY) Class Definition: (i) all persons who purchased the common stock of Dentsply Sirona, Inc. between February 20, 2014 and August 7, 2018; (ii) all Dentsply International Inc. shareholders who held shares as of the record date of December 2, 2015 and were entitled to vote with respect to the Acquisition at the January 11, 2016 special meeting of Dentsply International Inc. shareholders; and (iii) all persons who purchased or otherwise acquired the common stock of Dentsply International in exchange for their shares of common stock of Sirona in connection with the Acquisition Lead Plaintiff Deadline: February 19, 2019 Join the action: https://www.zlk.com/pslra-1/dentsply-sirona-inc-loss-form?wire=3
According to the complaint, during the Class Period, Defendants attributed the Company’s financial performance to the Company’s “innovation,” “operational improvement efforts,” “new products,” and “continued investments in sales and marketing” and told investors that these factors helped the Company succeed despite the “highly competitive” market for its products. In reality, the Company’s financial results had been buoyed by an anticompetitive scheme among the Company’s three primary distributors that suppressed competition in the dental supply market and artificially inflated the price of dental supplies sold by Dentsply. Further, Defendants concealed that an exclusive distribution arrangement that Sirona had with one of its distributors, Patterson Companies, Inc. (“Patterson”), required Patterson to regularly make large minimum purchases regardless of demand and, as a result, by 2015, Patterson had been supplied with so much excess inventory that it could not be sold. This channel-stuffing rendered the Company’s reported sales, financial results and guidance materially false and misleading. In addition, the Company represented that it reported its financial statements, including its goodwill, in accordance with generally accepted accounting principles, or GAAP. In fact, the Company’s reported goodwill was artificially inflated and not reported in accordance with GAAP because it did not reflect the financial impact of the anticompetitive scheme.
To learn more about the Dentsply Sirona, Inc. class action contact firstname.lastname@example.org.
Allergan plc (NYSE: AGN) Class Period: May 9, 2017 - December 19, 2018 Lead Plaintiff Deadline: February 19, 2019 Join the action: https://www.zlk.com/pslra-1/allergan-plc-loss-form?wire=3
During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various “pharma and device approvals” and concealed the fact that the Company’s CE Mark for its textured breast implants and tissue expanders was expiring in Europe. On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du Médicament (“ANSM”), the French regulatory authority, the Company had suspended the sale of these products and that it was withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the company’s CE Mark for these products, and the stock price fell drastically following the news.
To learn more about the Allergan plc class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY 10006 firstname.lastname@example.org Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com